STAA News and Press, STAAR Surgical Company

2024-06-13 06:36:02 ET Summary STAAR Surgical saw steady growth in business and market share, driven by the EVO ICL Lens, an alternative solution for nearsightedness. The company outlined ambitious three-year plans for significant revenue growth. Shares experienced significant...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...

2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 21:41:09 ET STAAR Surgical Company (STAA) Q1 2024 Results Conference Call May 07, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Call Participants Margaret Kaczor - Wi...

2024-05-07 16:19:31 ET More on STAAR Surgical STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript ...

EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ: K), a leading developer, manufactu...

Agreement is Largest Commitment to EVO ICL™ in the U.S. STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another m...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 17:35:20 ET More on STAAR Surgical STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript ...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 2...